Drug Discovery World

NOVEMBER 14, 2022

Alternative to insulin. A collaboration between PerkinElmer’s SIRION Biotech business and the Centre for Genomic Regulation (CRG) agreed to jointly develop new generation adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy in the pancreas. . AAV vectors for diabetes gene therapy.

Development 52

Development Gene Therapy Drugs Gene 52

Delveinsight

DECEMBER 7, 2020

In May 2020, Freenome initiated AI-EMERGE, a clinical study for the AI-Genomics blood test has been completed, which collected samples from up to 3,000 patients in the US and Canada. The device is worn on the patients’ body, which contains a biharmonic cartridge in it that carries insulin and glucagon.

Protein 56

Protein Insulin Hormones FDA Approval 56

pharmaphorum

SEPTEMBER 1, 2020

The first was insulin – Frederick Banting and colleagues managed to isolate insulin that could treat diabetes, up until that point a fatal condition. The period between 1918 and 1939 was marked by two breakthroughs that presaged the arrival of the pharma industry as we know it today. New challenges in an age of innovation.

Medicine 145

Medicine Insulin Pharmacy Drugs 145

Drug Discovery World

SEPTEMBER 6, 2022

Research into genomic medicines is only at its infancy. CellTrans is currently awaiting an FDA decision for its cell therapy Lantidra, a treatment for patients with brittle type 1 diabetes mellitus whose symptoms cannot be well managed despite insulin therapy.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

DECEMBER 31, 2020

Rhesus Macaque Genome Reference Includes 85 Million Genetic Variants. Researchers at Baylor College of Medicine , the University of Missouri and the University of Washington created a new reference genome assembly, identifying more than 85 million genetic variants in the rhesus macaque.

Antibody 52

Antibody Research Bacteria Genetics 52

The Pharma Data

JULY 23, 2021

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

Hormones 52

Hormones Trials Genome Genomics 52

The Pharma Data

MARCH 11, 2021

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

Trials 52

Trials Hormones Genome Genomics 52

The Pharma Data

MAY 17, 2021

At Illumina, the ‘era of the genome’ has arrived. Viatris Expects First “Interchangeable” Designation in July 2021 For Insulin Products ( Big Molecule Watch ). Viatris Expects First “Interchangeable” Designation in July 2021 For Insulin Products ( Big Molecule Watch ). Coronavirus Pandemic.

Trials 52

Trials Vaccination Vaccine Scientist 52